<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">Post-MMB survival was effectively predicted by an HR-weighted scoring of driver mutational status, presence or absence of 
 <italic>ASXL1</italic> and 
 <italic>SRSF2</italic> mutations, and age (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>). Comparison of MMB-treated patients with a risk-matched MF cohort not receiving treatment with MMB did not disclose significant difference in survival data (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>).
</p>
